Log in

NASDAQ:CTSO - Cytosorbents Stock Price, Forecast & News

$4.19
+0.18 (+4.49 %)
(As of 12/13/2019 04:00 PM ET)
Today's Range
$4.01
Now: $4.19
$4.27
50-Day Range
$3.61
MA: $4.35
$5.24
52-Week Range
$3.49
Now: $4.19
$9.25
Volume249,935 shs
Average Volume202,922 shs
Market Capitalization$135.84 million
P/E RatioN/A
Dividend YieldN/A
Beta1.64
Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology worldwide. The company's flagship product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CTSO
CUSIPN/A
Phone732-329-8885

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$22.50 million
Book Value$0.54 per share

Profitability

Net Income$-17,210,000.00

Miscellaneous

Employees125
Market Cap$135.84 million
Next Earnings Date3/5/2020 (Estimated)
OptionableOptionable

Receive CTSO News and Ratings via Email

Sign-up to receive the latest news and ratings for CTSO and its competitors with MarketBeat's FREE daily newsletter.


Cytosorbents (NASDAQ:CTSO) Frequently Asked Questions

What is Cytosorbents' stock symbol?

Cytosorbents trades on the NASDAQ under the ticker symbol "CTSO."

How were Cytosorbents' earnings last quarter?

Cytosorbents Corp (NASDAQ:CTSO) issued its quarterly earnings results on Tuesday, November, 5th. The medical research company reported ($0.21) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by $0.08. The medical research company had revenue of $6.10 million for the quarter, compared to analysts' expectations of $6.49 million. Cytosorbents had a negative net margin of 87.79% and a negative return on equity of 165.00%. View Cytosorbents' Earnings History.

When is Cytosorbents' next earnings date?

Cytosorbents is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Cytosorbents.

What price target have analysts set for CTSO?

3 Wall Street analysts have issued 12-month price targets for Cytosorbents' shares. Their forecasts range from $8.00 to $13.00. On average, they anticipate Cytosorbents' stock price to reach $11.00 in the next year. This suggests a possible upside of 162.5% from the stock's current price. View Analyst Price Targets for Cytosorbents.

What is the consensus analysts' recommendation for Cytosorbents?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytosorbents in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cytosorbents.

What are Wall Street analysts saying about Cytosorbents stock?

Here are some recent quotes from research analysts about Cytosorbents stock:
  • 1. Maxim Group analysts commented, "Cytosorbents reported 4Q18 with $5.5M in product sales, up 7% from $5.1M in 3Q18 and 30% from $4.2M y/y. For the year, revenue was $22.5M, a new record for the company and the first time revenue exceeded $20M. The company reported net income of ($5.4M) and $22.4M in cash." (3/8/2019)
  • 2. HC Wainwright analysts commented, "We maintain our Buy rating of CytoSorbents and our 12-month price target of $15.00 per share. We derive our price target based on the average of two valuation methods: 1) price-sales multiple using 7x 2025 sales estimate discounted at 12%; and 2) price-earnings multiple using 25x 2025 earnings estimate discounted at 12%. (1) commercial; (2) partnership; (3) clinical; (4) financial; and (5) intellectual property." (3/8/2019)

Has Cytosorbents been receiving favorable news coverage?

Press coverage about CTSO stock has trended somewhat negative this week, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Cytosorbents earned a media sentiment score of -1.8 on InfoTrie's scale. They also gave media headlines about the medical research company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Cytosorbents.

Are investors shorting Cytosorbents?

Cytosorbents saw a decrease in short interest during the month of November. As of November 29th, there was short interest totalling 2,320,000 shares, a decrease of 6.1% from the November 14th total of 2,470,000 shares. Based on an average daily volume of 161,500 shares, the short-interest ratio is presently 14.4 days. Approximately 7.6% of the shares of the stock are short sold. View Cytosorbents' Current Options Chain.

Who are some of Cytosorbents' key competitors?

What other stocks do shareholders of Cytosorbents own?

Who are Cytosorbents' key executives?

Cytosorbents' management team includes the folowing people:
  • Dr. Phillip P. Chan, CEO, Pres & Director (Age 49)
  • Ms. Kathleen P. Bloch MBA, CPA, CFO & Sec. (Age 64)
  • Mr. Vincent J. Capponi MS, Chief Operating Officer (Age 61)
  • Dr. Eric R. Mortensen, Chief Medical Officer (Age 59)
  • Dr. Robert H. Bartlett, Co-Chairman of Cardiac Surgery Advisory Board & Consultant (Age 80)

Who are Cytosorbents' major shareholders?

Cytosorbents' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Skylands Capital LLC (2.40%), Granahan Investment Management Inc. MA (2.05%), State Street Corp (1.57%), Sargent Investment Group LLC (0.92%), Bradley Foster & Sargent Inc. CT (0.14%) and Crow Point Partners LLC (0.13%). Company insiders that own Cytosorbents stock include Al Kraus, Kathleen P Bloch, Phillip P Chan and Vincent Capponi. View Institutional Ownership Trends for Cytosorbents.

Which major investors are selling Cytosorbents stock?

CTSO stock was sold by a variety of institutional investors in the last quarter, including Bradley Foster & Sargent Inc. CT, Sargent Investment Group LLC, State Street Corp, Barclays PLC and Crow Point Partners LLC. View Insider Buying and Selling for Cytosorbents.

Which major investors are buying Cytosorbents stock?

CTSO stock was acquired by a variety of institutional investors in the last quarter, including Granahan Investment Management Inc. MA, Skylands Capital LLC and Cadence Capital Management LLC. Company insiders that have bought Cytosorbents stock in the last two years include Kathleen P Bloch and Phillip P Chan. View Insider Buying and Selling for Cytosorbents.

How do I buy shares of Cytosorbents?

Shares of CTSO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Cytosorbents' stock price today?

One share of CTSO stock can currently be purchased for approximately $4.19.

How big of a company is Cytosorbents?

Cytosorbents has a market capitalization of $135.84 million and generates $22.50 million in revenue each year. The medical research company earns $-17,210,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis. Cytosorbents employs 125 workers across the globe.View Additional Information About Cytosorbents.

What is Cytosorbents' official website?

The official website for Cytosorbents is http://www.cytosorbents.com/.

How can I contact Cytosorbents?

Cytosorbents' mailing address is 7 DEER PARK DRIVE SUITE K, MONMOUTH JUNCTION NJ, 08852. The medical research company can be reached via phone at 732-329-8885 or via email at [email protected]


MarketBeat Community Rating for Cytosorbents (NASDAQ CTSO)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  394 (Vote Outperform)
Underperform Votes:  172 (Vote Underperform)
Total Votes:  566
MarketBeat's community ratings are surveys of what our community members think about Cytosorbents and other stocks. Vote "Outperform" if you believe CTSO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTSO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/14/2019 by MarketBeat.com Staff

Featured Article: Price Target

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel